Fig. 6From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapyDifference in overall survival and progression-free survival in patients with or without extrahepatic disease (excluding lymph node involvement)Back to article page